Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Cash & Equivalents (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Cash & Equivalents for 6 consecutive years, with $38.3 million as the latest value for Q3 2025.

  • Quarterly Cash & Equivalents rose 4089.72% to $38.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $38.3 million through Sep 2025, up 4089.72% year-over-year, with the annual reading at $97.5 million for FY2024, 963.81% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $38.3 million at Inhibikase Therapeutics, down from $77.7 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $97.5 million in Q4 2024, with the low at $913420.0 in Q3 2024.
  • Average Cash & Equivalents over 5 years is $28.8 million, with a median of $14.9 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents soared 601525.64% in 2021, then tumbled 94.09% in 2023.
  • Over 5 years, Cash & Equivalents stood at $40.8 million in 2021, then plummeted by 82.36% to $7.2 million in 2022, then rose by 27.5% to $9.2 million in 2023, then skyrocketed by 963.81% to $97.5 million in 2024, then plummeted by 60.75% to $38.3 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $38.3 million, $77.7 million, and $73.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.